Molecular Partners AG (MOLN)
5.42
+0.22
(+4.23%)
USD |
NASDAQ |
Nov 21, 16:00
5.71
+0.29
(+5.35%)
After-Hours: 06:51
Molecular Partners Revenue (Quarterly): 0.7875M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.7875M |
| June 30, 2024 | 1.715M |
| March 31, 2024 | 3.133M |
| December 31, 2023 | 1.164M |
| September 30, 2023 | 2.877M |
| June 30, 2023 | 0.4617M |
| March 31, 2023 | 3.293M |
| December 31, 2022 | 2.799M |
| September 30, 2022 | 2.420M |
| Date | Value |
|---|---|
| June 30, 2022 | 12.17M |
| March 31, 2022 | 187.06M |
| December 31, 2021 | 1.926M |
| September 30, 2021 | 3.842M |
| June 30, 2021 | 3.528M |
| March 31, 2021 | 0.901M |
| December 31, 2020 | 1.709M |
| September 30, 2020 | 0.3077M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.3077M
Minimum
Sep 2020
187.06M
Maximum
Mar 2022
13.54M
Average
2.420M
Median
Sep 2022
Revenue (Quarterly) Benchmarks
| AC Immune SA | 29.47M |
| CRISPR Therapeutics AG | -- |
| Addex Therapeutics Ltd | 0.1275M |
| NLS Pharmaceutics Ltd | -- |
| MoonLake Immunotherapeutics | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -18.97M |
| Total Expenses (Quarterly) | 17.66M |
| EPS Diluted (Quarterly) | -0.5666 |
| Enterprise Value | 28.94M |
| Profit Margin (Quarterly) | -2.41K% |
| Earnings Yield | -39.51% |
| Normalized Earnings Yield | -37.39 |